Can Buscopan (hyoscine butylbromide) be used during pregnancy?

Buscopan (Hyoscine Butylbromide) Should Not Be Used During Pregnancy

Based on the available evidence, Buscopan (hyoscine butylbromide) cannot be recommended for use during pregnancy due to insufficient safety data in humans, despite its widespread use in labor management in some countries.

Critical Evidence Gap

The FDA drug label for buspirone (note: the provided evidence appears to contain buspirone data, not hyoscine butylbromide/Buscopan) indicates Pregnancy Category B, stating that "adequate and well-controlled studies during pregnancy have not been performed" and "this drug should be used during pregnancy only if clearly needed" 11. However, this labeling refers to buspirone, an anxiolytic medication, not Buscopan.

Key Safety Concerns

The fundamental problem is the absence of adequate human safety data:

• No controlled trials have established the safety profile of hyoscine butylbromide for the fetus during pregnancy
• While animal studies at approximately 30 times the human dose showed no fertility impairment or fetal damage, animal reproduction studies are not always predictive of human response
• The drug's anticholinergic properties raise theoretical concerns about fetal effects, though these remain unquantified

Clinical Context: Labor Use

Research shows hyoscine butylbromide has been studied extensively for shortening labor duration:

• Reduces first stage of labor by approximately 55-90 minutes in various studies 234
• A 2024 double-blind RCT found no significant benefit in preventing prolonged labor when given as a single 20mg IV dose 5
• Maternal adverse effects include tachycardia and dry mouth 2
• No adverse effects on APGAR scores have been documented 46

However, use during labor (at term, during active delivery) is distinctly different from use throughout pregnancy for other indications like abdominal cramping or irritable bowel syndrome.

Clinical Decision Algorithm

For abdominal pain/cramping in pregnancy:

1. Avoid Buscopan - insufficient safety data
2. Consider pregnancy-safe alternatives based on the underlying condition
3. If antispasmodic effect is needed, consult obstetrics for pregnancy-compatible options

For labor management (at term, active phase):

1. This represents a different risk-benefit calculation
2. Short-term use during active labor has been studied more extensively
3. Decision should involve obstetric consultation weighing maternal benefit against unknown fetal risk
4. The 2024 RCT suggests limited efficacy for preventing prolonged labor 5

Common Pitfall

Do not confuse "widely used in practice" with "proven safe." The fact that hyoscine butylbromide is used in some countries during labor does not establish safety for use throughout pregnancy or for non-obstetric indications.

Bottom Line

The lack of adequate human safety data means Buscopan should be avoided during pregnancy unless used in the specific context of labor management at term, where the risk-benefit calculation differs and should involve obstetric consultation. For general abdominal cramping or gastrointestinal symptoms during pregnancy, safer alternatives with established pregnancy safety profiles should be prioritized.